Overview

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Panitumumab plus bortezomib for colon cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Georgetown University
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
Antibodies, Monoclonal
Bortezomib
Panitumumab